These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33687857)

  • 41. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
    Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
    Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
    Kim JH; Ahn SH; Ko SY; Choe WH; Kim KH; Kwon SY
    Clin Mol Hepatol; 2016 Jun; 22(2):241-9. PubMed ID: 27304549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
    Buti M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():32-8. PubMed ID: 19100229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
    Yegin EG; Ozdogan OC
    Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):602-11. PubMed ID: 25475862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
    Cuenca-Gómez JÁ; Lozano-Serrano AB; Cabezas-Fernández MT; Soriano-Pérez MJ; Vázquez-Villegas J; Estévez-Escobar M; Cabeza-Barrera I; Salas-Coronas J
    BMC Infect Dis; 2018 Nov; 18(1):568. PubMed ID: 30428845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 47. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
    Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
    Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?
    Liaw YF
    Hepatology; 2007 Feb; 45(2):266-8. PubMed ID: 17256763
    [No Abstract]   [Full Text] [Related]  

  • 51. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
    Hall S; Howell J; Visvanathan K; Thompson A
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32854335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
    Yim HJ
    Clin Mol Hepatol; 2016 Jun; 22(2):238-40. PubMed ID: 27377908
    [No Abstract]   [Full Text] [Related]  

  • 55. Adefovir dipivoxil in chronic hepatitis B infection.
    Yuen MF; Lai CL
    Expert Opin Pharmacother; 2004 Nov; 5(11):2361-7. PubMed ID: 15500383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
    Liu Y; Wang C; Zhong Y; Chen L; Li X; Ji D; Wang H; Xin S; Zoulim F; Xu D
    Antivir Ther; 2010; 15(8):1185-90. PubMed ID: 21149926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ
    J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
    Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
    J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
    Hosaka T; Suzuki F; Kumada H
    Nihon Shokakibyo Gakkai Zasshi; 2011 Feb; 108(2):210-4. PubMed ID: 21307624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.